
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
Long-term safety and efficacy clinical trial data (NCT03307980) for patients with hemophilia B administered the recombinant adeno-associated virus (AAV) vector gene therapy Beqvez (fidanacogene elaparvovec) show sustained factor IX expression, low bleeding …